Company news

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) news

Aurinia Pharmaceuticals Inc news releases on 6ix. Latest, Aug 6, 2026: Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended…

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) news

Press releases & updates

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

TANG CAPITAL MANAGEMENT, LLC FILES EARLY WARNING REPORT RESPECTING AURINIA PHARMACEUTICALS INC.

Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Aurinia Announces Management Transition

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Responds to Now Retracted LinkedIn Post

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025

New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025

Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting

ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development

Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth

Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024

Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024

Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis

Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference

Aurinia Announces Board Restructuring

Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial

Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results

Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024

Aurinia to Participate in Upcoming Investor Healthcare Conferences

Aurinia Announces 2024 Annual General Meeting Results

Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024

Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce

Aurinia Provides Update on Proxy Statement

Aurinia Will Attend 2024 Jefferies Global Healthcare Conference

Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024

Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024